| Autor: |
Shinya, Yamamoto, Kazutaka, Narui, Takashi, Ishikawa, Shoko, Adachi, Kazuhiro, Shimada, Daisuke, Shimizu, Akimitsu, Yamada, Sadatoshi, Sugae, Mikiko, Tanabe, Mari, Oba, Satoshi, Morita, Takako, Doi, Satoshi, Hasegawa, Tomoyuki, Morita, Ayako, Kito, Takashi, Chishima, Yasushi, Ichikawa, Itaru, Endo |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Anticancer research. 41(3) |
| ISSN: |
1791-7530 |
| Popis: |
This study aimed to investigate the efficacy of first-line gemcitabine monotherapy for metastatic breast cancer (MBC) and its effect on health-related quality of life (HRQoL) compared with treatment of physician's choice (TPC).We enrolled 96 patients into the first-line gemcitabine group (n=47) or other treatment of physician's choice (TPC) group (n=49) from May 2010 to April 2013. HRQoL was evaluated every 4 weeks.There was no significant difference in the median time to treatment failure (5.3 vs. 4.6 months, hazard ratio=0.87, p=0.546) and the incidence rates of grade 3/4 haematological toxicity (10.6% vs. 8.1%, p=0.677) and grade 3/4 non-haematological toxicity (4.2% vs. 8.1%, p=0.429) between the gemcitabine and TPC groups. Changes in HRQoL from baseline to 12 weeks were not significantly different.Gemcitabine achieves similar efficacy and HRQoL benefit to other chemotherapy and can be used as first-line treatment for MBC. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
